• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Inspire Medical Systems (INSP) After New CPT Codes With A Slightly Pricey Valuation

    Simply Wall St·10/10/2026 08:23:22
    Listen to the news

    Inspire Medical Systems (INSP) just picked up a key regulatory win, with the American Medical Association approving new Category I CPT codes for its Inspire V system, effective January 2028.

    For investors, the regulatory milestone lands against a mixed trading backdrop. Inspire Medical Systems’ share price stands at US$68.89 after a 1-day share price return of 3.30% and a 90-day share price return of 33.10%, yet the 1-year total shareholder return is still down 8.35% and the 5-year total shareholder return has fallen 71.90%, suggesting recent momentum has picked up after a much tougher multi year stretch.

    Scan 34 healthcare AI stocks that could benefit from similar reimbursement catalysts and growing demand for tech driven treatments alongside Inspire Medical Systems’ progress in obstructive sleep apnea therapy.

    Short term traders see a sharp rebound. Longer term holders see a stock still well below past highs. For Inspire Medical Systems at US$68.89 after this CPT news, is it better to lean into the move now or wait for a cheaper entry?

    Most Popular Narrative: 8% Overvalued

    At a last close of $68.89 against a narrative fair value of $63.80, Inspire Medical Systems screens as slightly rich, with that gap explained mostly by how investors weigh reimbursement stability against execution hiccups.

    Normalization of coding and reimbursement for Inspire Medical Systems, including clearer pathways across payers in 2026 and the AMA approval of new Category I CPT codes effective January 1, 2028, is expected to simplify billing and can support steadier procedure revenue and operating margins once current disruptions roll off.

    See why 9 investors see Inspire Medical Systems as 8% overvalued.

    Result: Fair Value of $63.80 (OVERVALUED)

    Still, the thesis around reimbursement clarity can crack if WISeR related disruption lingers or if legal scrutiny around Inspire Medical Systems’ launch disclosures intensifies.

    Find out about the key risks to this Inspire Medical Systems narrative.

    Another View: Inspire Medical Systems Through The Earnings Lens

    The narrative fair value pins Inspire Medical Systems at $63.80 and calls the stock 8% overvalued. The preferred P/E view points in a different direction. INSP trades on 14.7x earnings compared with 24.2x for the US Medical Equipment industry, peers at 35.5x, and a fair ratio of 20.1x. That gap suggests the market is pricing in extra execution risk, so the key question is whether you think those risks justify such a discount or eventually narrow.

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:INSP P/E Ratio as at Oct 2026
    NYSE:INSP P/E Ratio as at Oct 2026

    Next Steps

    If this mix of optimism and concern around Inspire Medical Systems feels familiar, let it push you to check the numbers yourself and move promptly to your own call by weighing the 3 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Inspire Medical Systems?

    If Inspire Medical Systems has your attention, do not stop here. Broaden your watchlist with other potential opportunities before the next move leaves you catching up.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.